Early steroids after pediatric liver transplantation protect against T-cell-mediated rejection: Results from the ChilSFree study.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
17
03
2023
accepted:
14
08
2023
pubmed:
8
9
2023
medline:
8
9
2023
entrez:
7
9
2023
Statut:
aheadofprint
Résumé
Steroid-free immunosuppression protocols gained popularity in pediatric liver transplantation (pLT) after the introduction of IL-2-receptor blockade for induction therapy. We analyzed the clinical and immunologic outcome data of the multicenter prospective observational ChilSFree study to compare the impact of steroid-free versus steroid-containing immunosuppressive therapy following pLT in a real-life scenario. Two hundred forty-six children [55.3% male, age at pLT median: 2.4 (range: 0.2-17.9) y] transplanted for biliary atresia (43%), metabolic liver disease (9%), acute liver failure (4%), hepatoblastoma (9%), and other chronic end-stage liver diseases (39%) underwent immune monitoring and clinical data documentation over the first year after pLT. Patient and graft survival at 1 year was 98.0% and 92.7%, respectively. Primary immunosuppression was basiliximab induction followed by tacrolimus (Tac) monotherapy (55%), Tac plus steroid tapering over 3 months (29%), or cyclosporine and steroid tapering (7%). One center used intraoperative steroids instead of basiliximab followed by Tac plus mycophenolate mofetil (7% of patients). N = 124 biopsy-proven T-cell-mediated rejections were documented in n = 82 (33.3%) patients. T-cell-mediated rejection occurred early (median: 41 d, range: 3-366 d) after pLT. Patients initially treated with Tac plus steroids experienced significantly fewer episodes of rejection than patients treated with Tac alone (chi-square p <0.01). The use of steroids was associated with earlier downregulation of proinflammatory cytokines interferon (IFN)-γ, Interleukin (IL)-6, CX motif chemokin ligand (CXCL)8, IL-7, and IL-12p70. Both primary immunosuppression with Tac plus steroids and living donor liver transplantation were independent predictors of rejection-free survival 1 year after pLT on logistic regression analysis. Adjunctive steroid therapy after pLT leads to earlier suppression of the post-pLT proinflammatory response and significantly reduced rejection rates during the first year after pLT (15.9%). Fifty-one percent of patients initially treated without steroids remain steroid-free over the first 12 months without rejection.
Identifiants
pubmed: 37678230
doi: 10.1097/LVT.0000000000000255
pii: 01445473-990000000-00242
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Association for the Study of Liver Diseases.
Références
van Mourik ID, Kelly DA. Immunosuppressive drugs in pediatric liver transplantation. Paediatr Drugs. 2001;3:43–60.
Al-Sinani S, Dhawan A. Corticosteroids usage in pediatric liver transplantation: To be or not to be!. Pediatr Transplant. 2009;13:160–170.
Toyoki Y, Hakamada K, Narumi S, Totsuka E, Nara M, Ono H, et al. Primary immunosuppression regimen of rapid steroid withdrawal after living related liver transplantation: a single-center experience. Transplant Proc. 2004;36:2279–2281.
Spada M, Petz W, Bertani A, Riva S, Sonzogni A, Giovannelli M, et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. Am J Transplant. 2006;6:1913–1921.
Reding R, Gras J, Sokal E, Otte JB, Davies HF. Steroid-free liver transplantation in children. Lancet. 2003;362:2068–2070.
Gras JM, Gerkens S, Beguin C, Janssen M, Smets F, Otte JB, et al. Steroid-free, tacrolimus-basiliximab immunosuppression in pediatric liver transplantation: clinical and pharmacoeconomic study in 50 children. Liver Transpl. 2008;14:469–477.
Leiskau C, Samuel S, Pfister ED, Junge N, Beneke J, Stupak J, et al. Low-dose steroids do make a difference: independent risk factors for impaired linear growth after pediatric liver transplantation. Pediatr Transplant. 2021;25:e13989.
Slowik V, Lerret SM, Lobritto SJ, Voulgarelis S, Vitola BE. Variation in immunosuppression practices among pediatric liver transplant centers—Society of Pediatric Liver Transplantation survey results. Pediatr Transplant. 2021;25:e13873.
Agarwal A, Pescovitz MD. Immunosuppression in pediatric solid organ transplantation. Semin Pediatr Surg. 2006;15:142–152.
Goldschmidt I, Karch A, Mikolajczyk R, Mutschler F, Junge N, Pfister ED, et al. Immune monitoring after pediatric liver transplantation—the prospective ChilSFree cohort study. BMC Gastroenterol. 2018;18:63.
Liu L, Wei L, Qu W, Liu Y, Zeng Z, Zhang H, et al. Impact of the Kasai procedure and the length of native liver survival time on outcomes of liver transplantation for biliary atresia. Liver Transpl. 2022;28:224–235.
Karakayali F, Kirnap M, Akdur A, Tutar N, Boyvat F, Moray G, et al. Biliary complications after pediatric liver transplantation. Transplant Proc. 2013;45:3524–3527.
Stevens JP, Xiang Y, Leong T, Naik K, Gupta NA. Portal vein complications and outcomes following pediatric liver transplantation: Data from the Society of Pediatric Liver Transplantation. Liver Transpl. 2022;28:1196–1206.
Badawy A, Brunner SM, Knoppke B, Volkl M, Junger H, Loss M, et al. Predictors of portal vein complications after pediatric liver transplantation: A German center experience. Pediatr Transplant. 2022;26:e14298.
Hussaini T, Turgeon RD, Partovi N, Erb SR, Scudamore CH, Yoshida EM. Immunosuppression practices in liver transplantation: a survey of North American centers. Exp Clin Transplant. 2018;16:550–553.
Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial. Lancet. 2004;364:1054–1061.
Lloyd C, Arshad A, Jara P, Burdelski M, Gridelli B, Manzanares J, et al. Long-term follow-up of a randomized trial of tacrolimus or cyclosporine A microemulsion in children post liver transplantation. Transplant Direct. 2021;7:e765.
Bourdeaux C, Pire A, Janssen M, Stephenne X, Smets F, Sokal E, et al. Prope tolerance after pediatric liver transplantation. Pediatr Transplant. 2013;17:59–64.
Riva N, Dip M, Halac E, Caceres Guido P, Woillard JB, Licciardone N, et al. Survival time to biopsy-proven acute rejection and tacrolimus adverse drug reactions in pediatric liver transplantation. Ther Drug Monit. 2018;40:401–410.
Minguela A, Torio A, Marin L, Sanchez-Bueno F, Garcia-Alonso AM, Ontanon J, et al. Implication of Th1, Th2, and Th3 cytokines in liver graft acceptance. Transplant Proc. 1999;31:519–520.
Gras J, Wieers G, Vaerman JL, Truong DQ, Sokal E, Otte JB, et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl. 2007;13:426–433.
Millan O, Benitez C, Guillen D, Lopez A, Rimola A, Sanchez-Fueyo A, et al. Biomarkers of immunoregulatory status in stable liver transplant recipients undergoing weaning of immunosuppressive therapy. Clin Immunol. 2010;137:337–346.
Millan O, Brunet M. Cytokine-based immune monitoring. Clin Biochem. 2016;49:338–346.
Millan O, Rafael-Valdivia L, San SD, Boix F, Castro-Panete MJ, Lopez-Hoyos M, et al. Should IFN-gamma, IL-17 and IL-2 be considered predictive biomarkers of acute rejection in liver and kidney transplant? Results of a multicentric study. Clin Immunol. 2014;154:141–154.
Millan O, Rafael-Valdivia L, Torrademe E, Lopez A, Fortuna V, Sanchez-Cabus S, et al. Intracellular IFN-gamma and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine. 2013;61:556–564.
Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, et al. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004;77:339–344.
Brunet M, Millan LO, Lopez-Hoyos M. T-cell cytokines as predictive markers of the risk of allograft rejection. Ther Drug Monit. 2016;38(suppl 1):S21–S28.
Millan O, Ruiz P, Fortuna V, Navasa M, Brunet M. Nuclear factor of activated T cells as potential pharmacodynamic biomarker for the risk of acute and subclinical rejection in de novo liver recipients. Liver Int. 2020;40:931–946.
Zant R, Melter M, Knoppke B, Ameres M, Kunkel J. Kinetics of interleukin-6, procalcitonin, and C-reactive protein after pediatric liver transplantation. Transplant Proc. 2014;46:3507–3510.
Ronca V, Wootton G, Milani C, Cain O. The immunological basis of liver allograft rejection. Front Immunol. 2020;11:2155.
Diem HV, Sokal EM, Janssen M, Otte JB, Reding R. Steroid withdrawal after pediatric liver transplantation: a long-term follow-up study in 109 recipients. Transplantation. 2003;75:1664–1670.
Kosola S, Lampela H, Jalanko H, Makisalo H, Lohi J, Arola J, et al. Low-dose steroids associated with milder histological changes after pediatric liver transplantation. Liver Transpl. 2013;19:145–154.
Hartleif S, Hodson J, Lloyd C, Cousin VL, Czubkowski P, D’Antiga L, et al. Long-term outcome of asymptomatic patients with graft fibrosis in protocol biopsies after pediatric liver transplantation. Transplantation. 2023. doi:10.1097/TP.0000000000004603
doi: 10.1097/TP.0000000000004603
Maue DK, Mangus RS, Lutfi R, Hobson MJ, Rao GS, Nitu ME, et al. Practice variation in the immediate postoperative care of pediatric liver transplant patients: Framework for a national consensus. Pediatr Transplant. 2021;25:e13976.